This shift protects MDS HSPCs from inflammatory damage and confers a proliferative advantage, suggesting that inhibiting the non-canonical NF-κB pathway can reverse the competitive survival of CSCs (95). Here, NFKB1 is linked to myelodysplastic syndrome.